NVPX
IMPL

Norwest Venture Partners XIV’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Norwest Venture Partners XIV’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$37.5M Hold
3,077,198
– – 62.06% 1
2021
Q2 		$27.2M Buy
+3,077,198
New +$36.7M 31.45% 2

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return

Norwest Venture Partners XIV's IMPL Position: Q3 2021 in Review

Norwest Venture Partners XIV held its Impel Pharmaceuticals Inc. Common Stock (IMPL) position steady in Q3 2021 at 3,077,198 shares worth $37.5M. The position accounts for 62.06% of the portfolio, ranked #1.

Norwest Venture Partners XIV first reported a position in IMPL in Q2 2021 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold IMPL as of Q3 2021.

  • Norwest Venture Partners XIV held 3,077,198 shares of Impel Pharmaceuticals Inc. Common Stock worth $37.5M as of Q3 2021.
  • Norwest Venture Partners XIV left its Impel Pharmaceuticals Inc. Common Stock share count unchanged in Q3 2021.
  • Impel Pharmaceuticals Inc. Common Stock made up 62.06% of Norwest Venture Partners XIV's portfolio in Q3 2021, its #1 holding.
  • Norwest Venture Partners XIV first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2021.

Based on Norwest Venture Partners XIV's 13F filing for Q3 2021, filed 27 Oct 2021.